On October 26, 2021 EpiAxis Therapeutics reported that it is among 25 emerging companies that will be showcased at Wholesale Investor’s STEM 2021 Conference on Thursday, October 28 (Press release, EpiAxis Therapeutics, OCT 26, 2021, View Source;utm_medium=rss&utm_campaign=epiaxis-to-present-at-stem-2021-conference [SID1234591924]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Breakthroughs in Science, Technology, Engineering, and Mathematics (STEM) have formed the foundation for critical disruptions across many industries and sectors in the last decade. STEM is the realm where our most significant problems are discovered, and the mechanism whereby these problems can be solved.

EpiAxis recently joined Wholesale Investor, Australasia’s leading investment platform that connects innovative, emerging companies that are looking to raise capital with an active, engaged and growing ecosystem of more than 29,300 high-net-worth investors, fund managers, family offices, PE and VC firms, government bodies and industry participants.

CEO Jeremy Chrisp will present at the Virtual Investor Showcase to raise awareness and visibility for EpiAxis’ epigenetic pipeline of therapies, which work differently to existing – and often toxic – cancer treatments by uniquely reprograming (re-train) the cancer cells back towards normal cells. Chrisp will discuss how our epigenetic science aims to maintain and extend cancer remission, with low side effects.

The showcase includes everything investors need to capitalise on STEM investment opportunities:

25 emerging companies solving problems in the space of; Renewable Energy, Life Sciences, AgriTech, FinTech, Data, and AI
Panel sessions from globally leading STEM investors discussing their due diligence process and sectors of interest
Live Q&A/interaction with panellists
Ability to conduct one-on-one meetings with founders of ventures

On October 25, 2021 X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, reported the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market.

"As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide," noted Matt Clark, Ph.D., CEO of X-Chem. "The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help biopharma clients of any size efficiently unlock exponential possibilities in small molecule drug discovery."

"Combining X-Chem, the world leader and pioneer of high-quality DEL technology, and ComInnex, a leader in the most important trends and novel approaches in early-stage drug discovery chemistry, will yield a powerhouse partner for innovative drug discovery solutions," commented Alex Drijver, CEO of ComInnex.

ComInnex’s technology expertise in flow chemistry, photochemistry and software development will expand X-Chem’s capabilities supporting the creation and delivery of innovative services for drug developers on a global scale.

(Press release, X-Chem, OCT 25, 2021, View Source [SID1234664774])

On October 25, 2021 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, reported it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021 (Press release, Delcath Systems, OCT 25, 2021, View Source [SID1234595188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

The call will also be available over the Internet and accessible at:

View Source

On October 25, 2021 Silenseed, a Tel Aviv RNAi company, reported that it raised $7.8 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund to start a China JV (Press release, Silenseed, OCT 25, 2021, View Source [SID1234593957]). Silenseed-China will own the rights to develop, market and sell Silenseed’s RNAi products in China. The Israeli company will use the capital to conduct a Phase III trial of its lead candidate, which targets the KRAS oncogene to treat pancreatic cancer. Silenseed’s novel drug delivery platform enables the insertion of RNAi therapeutics directly into solid tumors. GIBF will own a 49% stake in the Silenseed Chinese subsidiary.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 25, 2021, Oncotelic Therapeutics, Inc. (the "Company") reported that it entered into an Unsecured Convertible Note Purchase Agreement (the "Purchase Agreement") with Golden Mountain Partners, LLC (the ("Holder"), pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million (the "Note"), which Note is convertible into shares of the Company’s common stock, par value $0.01 per share ("Common Stock") (Filing, 8-K, Mateon Therapeutics, OCT 25, 2021, View Source [SID1234592110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Note carries an interest rate of 2% per annum and matures on the earlier of (a) the one-year anniversary of the date of the Agreement, or (b) the acceleration of the maturity of the Note by Holder upon occurrence of an Event of Default (as defined below). The Note contains a voluntary conversion mechanism whereby the Holder may convert the outstanding principal and accrued interest under the terms of the Note into shares of Common Stock (the "Conversion Shares"), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion (as defined in the Note) from Holder. Prepayment of the Note may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. The Note contains customary events of default (each an "Event of Default"). If an Event of Default occurs, at the Holder’s election, the outstanding principal amount of the Note, plus accrued but unpaid interest, will become immediately due and payable in cash. The Purchase Agreement requires the Company to use of the proceeds received under the Note to support the clinical development of OT-101, including payroll and has been made in continuation of the relationship between the Company and the Holder.

The issuance of the Note is exempt from the registration requirements of the Securities Act of 1933, as amended ("Securities Act"), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of Common Stock issuable upon conversion of the Note have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

The foregoing descriptions of the Purchase Agreement and the Note are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibit 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference.